NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE Drug Patent Profile
✉ Email this page to a colleague
When do Norepinephrine Bitartrate In 5% Dextrose patents expire, and when can generic versions of Norepinephrine Bitartrate In 5% Dextrose launch?
Norepinephrine Bitartrate In 5% Dextrose is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.
The generic ingredient in NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 5% Dextrose
A generic version of NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE was approved as norepinephrine bitartrate by MEITHEAL on March 3rd, 2003.
Summary for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 8 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE at DailyMed |
Recent Clinical Trials for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tunis University | Phase 4 |
Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
Wright State University | Phase 3 |
See all NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE clinical trials
Pharmacology for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
Drug Class | Catecholamine |
Anatomical Therapeutic Chemical (ATC) Classes for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare Corp | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214313-001 | Jan 15, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Baxter Hlthcare Corp | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214313-002 | Jan 15, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Baxter Hlthcare Corp | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | norepinephrine bitartrate | SOLUTION;INTRAVENOUS | 214313-003 | Nov 21, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |